Erin Robertson
Gerontology · Owasso, OKNPI 1639641202
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 25.5% of the total.
Across 105 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$433
- Pfizer$250
- Lilly USA, LLC$166
- Astellas Pharma US Inc$128
- AbbVie$124
- Abbott$102
- plus $498 from 15 others
What the payments were for
- Food & beverage$1,702100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $433 |
| Pfizer | 19 | $250 |
| Lilly USA, LLC | 10 | $166 |
| Astellas Pharma US Inc | 7 | $128 |
| AbbVie | 7 | $124 |
| Abbott | 6 | $102 |
| Amgen | 4 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Merck | 4 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Insulet Corporation | 1 | $32 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Novartis | 2 | $31 |
| Boehringer Ingelheim | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $28 |
| Johnson & Johnson | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| AstraZeneca | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| GSK | 1 | $14 |
How this compares
$1,702 in reported general payments places this provider in the 60th percentile of 73 gerontology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 107 | $123,625 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $61,082 |
| EliquisApixaban | 51 | $47,121 |
| JardianceEmpagliflozin | 34 | $40,051 |
| OzempicSemaglutide | 32 | $33,182 |
| JanuviaSitagliptin Phosphate | 12 | $19,967 |
| TrulicityDulaglutide | 14 | $19,498 |
| XareltoRivaroxaban | 12 | $10,081 |
| Omeprazole | 153 | $3,108 |
| Atorvastatin Calcium | 247 | $3,056 |
| Celecoxib | 72 | $2,737 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 119 | $2,718 |
| Gabapentin | 146 | $2,689 |
| SynthroidLevothyroxine Sodium | 17 | $2,348 |
| Levothyroxine Sodium | 208 | $2,029 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $166 | $143,123121 claims |
| GSKTrelegy Ellipta | $14 | $61,08265 claims |
| PfizerEliquis | $250 | $47,12151 claims |
| Boehringer IngelheimJardiance | $30 | $40,05134 claims |
| Novo NordiskOzempic | $433 | $33,18232 claims |
| MerckJanuvia | $62 | $19,96712 claims |
| Johnson & JohnsonXarelto | $20 | $10,08112 claims |
| AbbVieSynthroid | $124 | $2,34817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 73 gerontology providers in Oklahoma.
Other gerontology in Owasso
- Whitney SimmonsOklahoma City$40K
- Christy CovingtonOklahoma City$12K
- Amanda SpencerNorman$8K
- Shelley TriplettTulsa$7K
- Stacie HanesOklahoma City$6K
- Justin RobertsMuskogee$6K
- Kelly SpychalskiAda$6K
- Samantha TuckerNorman$6K
- Kjerista TiptonTulsa$6K
- Bailey StremmeTulsa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.